Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
Sue Ann Costa Clemens(The George Institute for Global Health), Laiana Januse de Arruda Cordeiro Matos, Ahmed Eldawi, Mayara Fraga(D’Or Institute for Research and Education), Danielle Woods(University of Oxford), Lily Yin Weckx(Hospital São Paulo), Reece Mabette, Helen Sanders, Liberty Cantrell(University of Oxford), Suzete Nascimento Farias da Guarda(Universidade Federal da Bahia), Piyada Supasa(University of Oxford), Chitra Tejpal, Sally Felle, Parvinder K. Aley(University of Oxford), Marta Ulaszewska, Xinxue Liu(University of Oxford), Zara Valliji, Isabela G. S. Gonzalez(Universidade Federal de São Paulo), Juthathip Mongkolsapaya(Centre for Human Genetics), Gracie Mead, Andrew J. Pollard(University of Oxford), Sagida Bibi(University of Oxford), Sophie Vernon, Thaiane Muniz Martins, Maristela Miyamoto de Nobrega(Universidade Federal de São Paulo), Wanwisa Dejnirattisai(Hammersmith Hospital), Claudia Loureiro Martins Medrado, Sophie Davies(University of Bath), Amy Beveridge, Isabelle Silva Queiroz Oliveira(D’Or Institute for Research and Education), Merryn Voysey(Stratasys (Israel)), Alessandra R. Souza(Universidade Federal de São Paulo), Bruno Solano de Freitas Souza(D’Or Institute for Research and Education), Gavin Screaton(University of Oxford), Marília Miranda Franco(D’Or Institute for Research and Education), Natalia Salvador(D’Or Institute for Research and Education), Juyeon Park(Harvard University), Ana Verena Almeida Mendes(Escola Bahiana de Medicina e Saúde Pública), Holly Smith, Ralf Clemens(University of Siena), Mariana B.V. Silveira(Universidade Federal de São Paulo), Renata Navis de Avila Mendonça(D’Or Institute for Research and Education), Teresa Lambe(Science Oxford), Maria Isabel de Moraes Pinto(Universidade Federal de São Paulo), Mustapha Bittaye(University of Oxford)
Cited by 467
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k